Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3053-3060

  Tewary, Poonam ^a   Sukumaran, Bindu ^a   Saxena, Shailendra ^a   Madhubala, Rentala ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

CpG odn; L. donovani; Recombinant ORFF antigen

Indexed keywords

BACTERIAL DNA; DINUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; NITRIC OXIDE; OLIGODEOXYNUCLEOTIDE; PARASITE ANTIGEN; RECOMBINANT ORFF LEISHMANIA ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; FEMALE; HELPER CELL; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; LEISHMANIA DONOVANI; MACROPHAGE; MALE; METHYLATION; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTECTION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; CELL DIVISION; CYTOKINES; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NITRIC OXIDE; NITRITES; OLIGONUCLEOTIDES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SPLEEN; VACCINES, SYNTHETIC;

EID: 3843131921     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.007     Document Type: Article

References (41)

1. Baily G., Nandy A. Visceral Leishmanisis: more prevalent and more problematic. J. Infect. 29:1994;241-247
2. Herwaldt B. Leishmaniasis. Lancet. 354:1999;1191-1199
3. World Health Report. Thirteenth programme report. Special programme for research and training in tropical diseases. Leishmaniasis. Geneva: World Health Organizations Publications; 1997.
4. World Health Organization. Advances in battle against Leishmaniasis. TDR News 1998;57:2.
5. Abdelhak S., Louzir H., Timm J., Blel L., Benlasfar Z., Lagranderie M., et al. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology. 141:1995;1585-1592
6. Alarcon J.B., Waine G.W., McManus D.P. DNA vaccines: technology and applications as anti-parasite and anti-microbial agents. Adv. Parasitol. 42:1999;343-410
7. Cox F.E. Designer vaccines for parasitic diseases. Int. J. Parasitol. 27:1997;1147-1157
8. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine. 19:2001;423-430
9. Cabrera M., Blackwell J.M., Castes M., Trujillo D., Convit J., Shaw M.A. Immunotherapy with live BCG plus heat killed leishmania induces a T helper-1 like response in American cutaneous leishmaniasis patients. Parasite Immunol. 22:2000;73-79
10. Handman E. Leishmania vaccines: old and new. Parasitol. Today. 13:1997;236-238
11. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to the mice infected with Leishmania major. J. Exp. Med. 186:1997;1137-1147
12. Sjolanader A., Baldwin T.M., Curtis J.M., Mandman E. Induction of a Th1 response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis. J. Immunol. 160:1998;3949-3957
13. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1 and Th2 derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine leishmaniasis. J. Immunol. 146:1991;2763-2770
14. Karp C.L., el-Safi S.H., Wynn T.A., Satti M.M., Kordofani A.M., Hashim F.A., et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 91:1993;1644-1648
15. Kemp M., Kurtzhals J.A., Bendtzen K., Poulsen L.K., Hansen M.B., Koech D.K., et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61:1993;1069-1073
16. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon gamma production by stimulation of IL-12 and tumor necrosis factor alpha. Cell Immunol. 167:1996;72-78
17. Klinman D., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFN-gamma. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2879-2883
18. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549
19. Cowdery J.S., Chase J.H., Yi A.K., Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:1996;4570-4575
20. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1991;1759-1764
21. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:1984;955-962
22. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10833-10837
23. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631
24. Davis H.L., Weeranta R., Waldshmidt T.J., Tygrett L., Schorr J., Krieg M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876
25. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854
26. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., Turon T.N., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J. Exp. Med. 195:2002;1565-1573
27. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Rocken M., Wagner H., et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160:1998;3627-3630
28. Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Leishmania donovani: characterization and expression of ORFF, a gene amplified from the LD1 locus. Exp. Parasitol. 93:1999;225-230
29. Myler P.J., Venkataraman G.M., Lodes M.J., Stuart K.D. A frequently amplified region in Leishmania contains a gene that is conserved in prokaryotes and eukaryotes. Gene. 148:1994;187-193
30. Tripp C.A., Wisdom W.A., Myler P.J., Stuart K.D. A multicopy, extrachromosomal DNA in Leishmania infantum contains two inverted repeats of the 27.5 kb LD1 sequence and encodes numerous transcripts. Mol. Biochem. Parasitol. 55:1992;39-50
31. Sukumaran B., Tewary P., Saxena S., Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine. 21:2003;1292-1299
32. 15N ] nitrate in biological fluids Anal. Biochem. 126:1982;131-138
33. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-gamma dependent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6970-6975
34. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25
35. Stacey K.J., Blackwell J.M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67:1999;3719-3726
36. Fisher RA, Yates F. Student's t-test of significance. In: statistical tables for agricultural and other research workers. Edinburg: Oliver and Boyd; 1957. p. 1024-9.
37. Shah J.A., Darrah P.A., Ambrozak D.R., Turon T.N., Mendez S., Kirman J., et al. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J. Exp. Med. 198:2003;281-291
38. Mendez S., Tabbara K., Belkaid Y., Bertholet S., Verthelyi D., Klinman D., et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 71:2003;5121-5129
39. Verthelyi D., Gursel M., Kenney R.T., Lifson J.D., Liu S., Mican J., et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170:2003;4717-4723
40. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application and optimization. Annu. Rev. Immunol. 18:2000;927-974
41. Datta N., Mukherjee S., Das L., Das P.K. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T-cell activation. Eur. J. Immunol. 33:2003;1508-1518